{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018418","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.631057+00:00","generated_at":"2026-06-02T06:25:07.342248+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Co-Diagnostics Q1 net loss $9.3M ($0.31/share), revenue $0.5M, down 17% YoY","bullets":["Revenue $0.5M ($0.3M product, $0.2M grant) vs $0.6M in Q1 2023.","Operating loss $10.3M, net loss $9.3M, vs $10.0M and $5.8M prior year.","Adjusted EBITDA loss $8.4M, up from $7.2M; cash & securities $50.0M.","Appointed four new executives: President Richard Abbott, COO, CTO, CCO.","Opened new manufacturing facility in Salt Lake; plans 510(k) submission for PCR Pro and COVID-19 test."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018418","json":"https://secwatch.observer/filing/0001493152-24-018418.json","markdown":"https://secwatch.observer/filing/0001493152-24-018418.md","text":"https://secwatch.observer/filing/0001493152-24-018418.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224018418/0001493152-24-018418-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224018418/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:25:07.342248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac4c1b851207eace2e2eddfc41f14f0891e7591b","claim":"Co-Diagnostics, Inc. reported quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss of $9.3 million, EPS loss of $0.31 per fully diluted share.","evidence_excerpt":"Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results SALT LAKE CITY, May 9, 2024— Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Dx,” or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Results: ● Revenue of $0.5 million, down from $0.6 million during the prior year. Grant revenue totaled $0.2 million while product revenue totaled $0.3 million ● Operating expenses of $10.5 million increased by 4.4% from the prior year due to an increase in research and development costs incurred for the development of tests currently in our pipeline ● Operating loss of $10.3 million compared to operating loss of $10.0 million in Q1 2023 ● Net loss of $9.3 million, compared to net loss of $5.8 million in the prior year, representing a loss of $0.31 per fully diluted share, compared to a loss of $0.20 per fully dilut","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224018418/0001493152-24-018418-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.5 million"},{"label":"Net income","value":"Net loss of $9.3 million"},{"label":"EPS","value":"loss of $0.31 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}